MUCOSAL MELANOMA
Clinical trials for MUCOSAL MELANOMA explained in plain language.
Never miss a new study
Get alerted when new MUCOSAL MELANOMA trials appear
Sign up with your email to follow new studies for MUCOSAL MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New trial aims to snuff out melanoma before it returns
Disease control Recruiting nowThis study is for people with high-risk melanoma who have had surgery to remove their cancer. It uses a blood test to find tiny bits of tumor DNA that might be left behind. Participants will receive either a standard immunotherapy or a combination of two immunotherapy drugs to se…
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 26, 2026 04:43 UTC
-
New hope for hard-to-treat melanoma: immunotherapy before surgery
Disease control Recruiting nowThis study tests new combinations of immunotherapy drugs given before surgery for people with advanced melanoma that is hard to treat. The goal is to see if these combinations can shrink or eliminate the tumor before it is removed, reducing the chance of the cancer coming back. A…
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New combo aims to block rare Melanoma's return
Disease control Recruiting nowThis study tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 adults with this rare type of melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The goal is to see whic…
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New radioactive drug targets tough melanoma
Disease control Recruiting nowThis early-stage trial tests an investigational drug for adults with melanoma that has spread or cannot be surgically removed. The main goals are to find the safest dose and understand side effects. Participants receive the drug once every 6 weeks for up to 6 doses, with regular …
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New hope for advanced skin cancers: first human trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also look at …
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE1 • Sponsor: Kupando GmbH • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New combo therapy offers hope for rare mucosal melanoma
Disease control Recruiting nowThis study tests whether combining two drugs, axitinib and nivolumab, can shrink or control advanced mucosal melanoma, a rare cancer that starts in moist lining tissues. About 20 people with untreated, advanced disease will receive the combination. If the cancer worsens, some may…
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New Shot-in-Tumor combo aims to shrink melanoma before surgery
Disease control Recruiting nowThis study tests whether injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgery can destroy more cancer cells and cause fewer side effects than standard treatment. About 50 adults with stage III melanoma that can be surgically re…
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
Promising combo therapy aims to keep rare melanoma from returning
Disease control Recruiting nowThis study is for people with a rare type of skin cancer called mucosal melanoma that has been completely removed by surgery and tests positive for PD-L1. The trial compares adding the immunotherapy drug sintilimab to standard chemotherapy versus chemotherapy alone to see if the …
Matched conditions: MUCOSAL MELANOMA
Phase: PHASE2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 22, 2026 13:50 UTC